See more : AGI Greenpac Limited (AGI.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Entera Bio Ltd. (ENTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entera Bio Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Corcel Exploration Inc. (CRCL.CN) Income Statement Analysis – Financial Results
- Gansu Yatai Industrial Developent Co., Ltd. (000691.SZ) Income Statement Analysis – Financial Results
- Transport Corporation of India Limited (TCI.BO) Income Statement Analysis – Financial Results
- Lyons Bancorp Inc. (LYBC) Income Statement Analysis – Financial Results
- Inovio Pharmaceuticals, Inc. (INO) Income Statement Analysis – Financial Results
Entera Bio Ltd. (ENTX)
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 134.00K | 571.00K | 365.00K | 236.00K | 500.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 56.00K | 101.00K | 373.00K | 209.00K | 210.00K | 0.00 | 43.00K | 35.00K | 28.00K |
| Gross Profit | -56.00K | 33.00K | 198.00K | 156.00K | 26.00K | 500.00K | -43.00K | -35.00K | -28.00K |
| Gross Profit Ratio | 0.00% | 24.63% | 34.68% | 42.74% | 11.02% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.51M | 5.85M | 6.77M | 6.40M | 7.20M | 8.52M | 2.77M | 2.65M | 2.12M |
| General & Administrative | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Other Expenses | 0.00 | -51.00K | -46.00K | 1.24M | 743.00K | 523.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.86M | 13.05M | 12.42M | 11.29M | 11.48M | 11.36M | 11.34M | 5.37M | 3.70M |
| Cost & Expenses | 8.86M | 13.15M | 12.79M | 11.50M | 11.69M | 11.36M | 11.34M | 5.37M | 3.70M |
| Interest Income | 31.00K | 83.00K | 0.00 | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 29.00K | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 56.00K | 64.00K | 53.00K | 63.00K | 238.00K | 54.00K | 43.00K | 35.00K | 28.00K |
| EBITDA | -8.80M | -12.87M | -12.16M | -11.11M | -11.35M | -10.81M | -11.05M | -5.33M | -3.67M |
| EBITDA Ratio | 0.00% | -9,714.18% | -2,130.30% | -3,050.14% | -4,752.54% | -2,161.40% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -13.02M | -12.22M | -11.13M | -11.45M | -10.86M | 11.34M | -5.37M | -3.70M |
| Operating Income Ratio | 0.00% | -9,714.18% | -2,139.58% | -3,050.14% | -4,853.39% | -2,172.20% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.00K | 134.00K | -29.00K | -28.00K | 659.00K | 557.00K | 146.00K | 4.17M | -581.00K |
| Income Before Tax | -8.86M | -12.93M | -12.25M | -9.96M | -10.80M | -10.30M | -11.20M | -1.20M | -4.28M |
| Income Before Tax Ratio | 0.00% | -9,652.24% | -2,144.66% | -2,729.59% | -4,574.15% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 29.00K | 137.00K | -59.00K | 20.00K | 84.00K | 557.00K | -146.00K | 0.00 | 0.00 |
| Net Income | -8.89M | -13.07M | -12.19M | -9.98M | -10.88M | -10.30M | -11.20M | -1.20M | -4.28M |
| Net Income Ratio | 0.00% | -9,754.48% | -2,134.33% | -2,735.07% | -4,609.75% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.30 | -1.31 | -0.14 | -0.36 |
| EPS Diluted | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.29 | -0.94 | -0.10 | -0.36 |
| Weighted Avg Shares Out | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.96M | 8.57M | 8.57M | 11.90M |
| Weighted Avg Shares Out (Dil) | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.98M | 11.90M | 11.90M | 11.90M |
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September...
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing...
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor...
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the...
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
Since 2021, meme stocks have been massive wealth creators for high-risk investors. During this period, dozens of meme stocks have delivered 5x to 10x returns within a few quarters.
Source: https://incomestatements.info
Category: Stock Reports